Breast Cancer

Immunomedics has resubmitted its biologics license application to the FDA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received ≥2 prior therapies for metastatic disease.

The UK National Institute for Health and Care Excellence has approved palbociclib in combination with fulvestrant for the treatment of female patients with hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.

Innovative clinical trials designed to exploit the explosion of data on the drivers of cancer are demonstrating value as tools to explore potential signals of efficacy across tumor types, according to oncology experts. These studies have become a feature of the drug discovery landscape in oncology and are likely to remain part of the fabric of clinical research in the genomic era.

Experts from West Cancer Center highlighted the exciting research being conducted at their institution.

Lee S. Schwartzberg, MD, FACP, discusses paradigm shifts in hormone receptor–positive breast cancer and triple-negative breast cancer.

We traveled to Raleigh, North Carolina, for a State of the Science Summit™ on Breast Cancer, which featured insights from the Duke Cancer Institute faculty.

Tiffany A. Traina, MD, discusses emerging therapies for the management of metastatic triple-negative breast cancer.

Komal Jhaveri, MD, FACP, discusses updates in research for metastatic HR-positive, HER2-negative breast cancer.

Joseph A. Sparano, MD, discusses using gene expression profiles as a means to guide therapy in breast cancer.

Adam M. Brufsky, MD, PhD, discusses remaining challenges in breast cancer.

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

Susan Domchek, MD, discusses the results of the phase II MEDIOLA trial in germline BRCA-mutated metastatic breast cancer.

Early dose reductions in a common adjuvant chemotherapy regimen were associated with inferior survival outcomes in a retrospective study of women with intermediate- to high-risk breast cancer.

Massimo Cristofanilli, MD, discusses adverse events caused by the use of aromatase inhibitors in breast cancer.

An updated biologics license application has been submitted to the FDA for eflapegrastim for the management of chemotherapy-induced neutropenia.

The FDA has issued a draft guidance to propose labeling recommendations, including a boxed warning, to breast implant manufacturers in an effort to help patients understand the benefits and risks of these devices.

Armando E. Giuliano, MD, a 2018 OncLive Giants of Cancer Care® award winner in Surgical Oncology, disrupted the treatment landscape for early breast cancer when he introduced sentinel lymph node biopsy. The result led to improved quality of life and reduced the need for radical breast cancer procedures for many patients.

Bernard Fisher, MD, a world-renowned physician/scientist and the chair of the National Surgical Adjuvant Breast and Bowel Project for more than 27 years, has died at the age of 101.

Gretchen G. Kimmick, MD, MS, discusses the management of patients with early-stage hormone receptor–positive, HER2-negative breast cancer.

In keeping up with the expanding breast cancer treatment armamentarium, we sat down with Jane L. Meisel, MD, and Aditya Bardia, MD, MPH, who shed light on emerging treatment strategies for patients with metastatic triple-negative breast cancer and discussed the optimal timing of genomic testing in women with progressive hormone receptor–positive disease.

New treatment approaches for patients with relapsed or refractory advanced breast cancer are making their way into clinical practice or are on the horizon.

Paul Kelly Marcom, MD, discusses the use of liquid biopsies in breast cancer treatment.

Updated results from the phase I/II MEDIOLA study strengthen the case for combining olaparib and durvalumab in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations. The updated data were featured in two separate presentations at the 2019 ESMO Congress.

Immunotherapy may finally be taking center stage in breast cancer, although much work remains to be done.

There is an unprecedented array of therapeutic options for patients with triple-negative breast cancer, with more approaches on the horizon.